Suppr超能文献

新型冠状病毒肺炎非重症患者临床恶化的预测因素:一项回顾性队列研究。

Predictors of clinical deterioration in non-severe patients with COVID-19: a retrospective cohort study.

作者信息

Yitao Zhang, Mu Chen, Ling Zhou, Shiyao Cheng, Jiaojie Xue, Zhichong Chen, Huajing Peng, Maode Ou, Kanglin Cheng, Mao Ou Yang, Xiaoneng Mo, Weijie Zeng

机构信息

The Cardiovascular Department, the Sixth Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.

Department of Pulmonology, Guangzhou Eighth People's Hospital, Guangzhou, China.

出版信息

Curr Med Res Opin. 2021 Mar;37(3):385-391. doi: 10.1080/03007995.2021.1876005. Epub 2021 Feb 4.

Abstract

OBJECTIVE

Coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) remains pandemic with considerable morbidity and mortality around the world. The aim of this study was to identify the predictors for clinical deterioration in patients with COVID-19 who did not show clinical deterioration upon hospital admission.

METHODS

Two hundred fifty-seven patients with confirmed COVID-19 pneumonia admitted to Guangzhou Eighth People's Hospital between 23 January and 21 March 2020 were retrospectively enrolled. Demographic data, symptoms, laboratory values, comorbidities and treatments were all collected. The study endpoint was clinical deterioration within 20 days from hospital admission. Univariate and multivariable logistic regression methods were used to explore the risk factors associated with clinical deterioration.

RESULTS

A total of 49 (19%) patients showed clinical deterioration after admission. Compared with patients that did not experience clinical deterioration, clinically deteriorated patients had more dyspnea, cough and myalgia (65.3% versus 29.3%) symptoms and more had comorbidities (89.8% versus 36.1%). Clinical and laboratory characteristics at admission that were associated with clinical deterioration included senior age, diabetes, hypertension, myalgia, higher temperature, systolic blood pressure, C-reactive protein (CRP), procalcitonin, activated partial thromboplastin time, aspartate aminotransferase, alanine transaminase, direct bilirubin, plasma creatinine, lymphocytopenia, thrombocytopenia, decreased albumin and bicarbonate concentration. Medical history of angiotensin-converting enzyme inhibitors/angiotensin receptor blockers, calcium channel blockers and metformin were also risk factors.

CONCLUSION

The four best predictors for clinical deterioration were CRP, procalcitonin, age and albumin. A "best" multivariable prediction model, resulting from using a variable selection procedure, included senior age, presentation with myalgia, and higher level of CRP and serum creatinine (bias-corrected -statistic = 0.909). Sensitivity and specificity corresponding to a cut point of CRP ≥18.45 mg/L for predicting clinical deterioration were 85% and 74%, respectively.

摘要

目的

由严重急性呼吸综合征冠状病毒2(SARS-CoV-2)引起的2019冠状病毒病(COVID-19)仍在全球大流行,导致相当高的发病率和死亡率。本研究的目的是确定入院时未出现临床恶化的COVID-19患者临床恶化的预测因素。

方法

回顾性纳入2020年1月23日至3月21日期间收治于广州市第八人民医院的257例确诊COVID-19肺炎患者。收集人口统计学数据、症状、实验室检查值、合并症及治疗情况。研究终点为入院后20天内的临床恶化情况。采用单因素和多因素logistic回归方法探讨与临床恶化相关的危险因素。

结果

共有49例(19%)患者入院后出现临床恶化。与未发生临床恶化的患者相比,发生临床恶化的患者有更多的呼吸困难、咳嗽和肌痛(65.3%对29.3%)症状,且合并症更多(89.8%对36.1%)。入院时与临床恶化相关的临床和实验室特征包括高龄、糖尿病、高血压、肌痛、体温较高、收缩压、C反应蛋白(CRP)、降钙素原、活化部分凝血活酶时间、天冬氨酸转氨酶、丙氨酸转氨酶、直接胆红素、血肌酐、淋巴细胞减少、血小板减少、白蛋白降低和碳酸氢盐浓度降低。血管紧张素转换酶抑制剂/血管紧张素受体阻滞剂、钙通道阻滞剂和二甲双胍的用药史也是危险因素。

结论

临床恶化的四个最佳预测因素为CRP、降钙素原、年龄和白蛋白。通过变量选择程序得出的“最佳”多因素预测模型包括高龄、有肌痛表现以及较高水平的CRP和血清肌酐(偏差校正后的 -统计量 = 0.909)。预测临床恶化的CRP切点≥18.45mg/L时,敏感性和特异性分别为85%和74%。

相似文献

1
Predictors of clinical deterioration in non-severe patients with COVID-19: a retrospective cohort study.
Curr Med Res Opin. 2021 Mar;37(3):385-391. doi: 10.1080/03007995.2021.1876005. Epub 2021 Feb 4.
5
Predictive role of clinical features in patients with coronavirus disease 2019 for severe disease.
Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2020 May 28;45(5):536-541. doi: 10.11817/j.issn.1672-7347.2020.200384.
7
C-reactive protein and procalcitonin for antimicrobial stewardship in COVID-19.
Infection. 2021 Oct;49(5):935-943. doi: 10.1007/s15010-021-01615-8. Epub 2021 May 22.
8
Do underlying cardiovascular diseases have any impact on hospitalised patients with COVID-19?
Heart. 2020 Aug;106(15):1148-1153. doi: 10.1136/heartjnl-2020-316909. Epub 2020 May 25.

引用本文的文献

1
Development and validation of nomogram models for severe and fatal COVID-19.
Sci Rep. 2024 Nov 25;14(1):29146. doi: 10.1038/s41598-024-80310-8.
2
Predicting Deterioration from Wearable Sensor Data in People with Mild COVID-19.
Sensors (Basel). 2023 Dec 4;23(23):9597. doi: 10.3390/s23239597.
3
Carbon dioxide and MAPK signalling: towards therapy for inflammation.
Cell Commun Signal. 2023 Oct 10;21(1):280. doi: 10.1186/s12964-023-01306-x.
4
Effects of the pre-existing coronary heart disease on the prognosis of COVID-19 patients: A systematic review and meta-analysis.
PLoS One. 2023 Oct 10;18(10):e0292021. doi: 10.1371/journal.pone.0292021. eCollection 2023.
5
Association between acute liver injury & severity and mortality of COVID-19 patients: A systematic review and meta-analysis.
Heliyon. 2023 Sep 20;9(9):e20338. doi: 10.1016/j.heliyon.2023.e20338. eCollection 2023 Sep.
6
Machine learning techniques to predict different levels of hospital care of CoVid-19.
Appl Intell (Dordr). 2022;52(6):6413-6431. doi: 10.1007/s10489-021-02743-2. Epub 2021 Sep 10.
7
Active pulmonary tuberculosis and coronavirus disease 2019: A systematic review and meta-analysis.
PLoS One. 2021 Oct 21;16(10):e0259006. doi: 10.1371/journal.pone.0259006. eCollection 2021.
8
Prevalence of comorbid tuberculosis amongst COVID-19 patients: A rapid review and meta-analysis.
Int J Clin Pract. 2021 Nov;75(11):e14867. doi: 10.1111/ijcp.14867.
9
Metformin in Patients With COVID-19: A Systematic Review and Meta-Analysis.
Front Med (Lausanne). 2021 Aug 19;8:704666. doi: 10.3389/fmed.2021.704666. eCollection 2021.

本文引用的文献

1
Risk Factors for Mortality in 244 Older Adults With COVID-19 in Wuhan, China: A Retrospective Study.
J Am Geriatr Soc. 2020 Jun;68(6):E19-E23. doi: 10.1111/jgs.16533. Epub 2020 May 12.
2
Prognostic value of interleukin-6, C-reactive protein, and procalcitonin in patients with COVID-19.
J Clin Virol. 2020 Jun;127:104370. doi: 10.1016/j.jcv.2020.104370. Epub 2020 Apr 14.
3
Risk factors of critical & mortal COVID-19 cases: A systematic literature review and meta-analysis.
J Infect. 2020 Aug;81(2):e16-e25. doi: 10.1016/j.jinf.2020.04.021. Epub 2020 Apr 23.
4
Association between age and clinical characteristics and outcomes of COVID-19.
Eur Respir J. 2020 May 27;55(5). doi: 10.1183/13993003.01112-2020. Print 2020 May.
5
Risk factors associated with disease severity and length of hospital stay in COVID-19 patients.
J Infect. 2020 Jul;81(1):e95-e97. doi: 10.1016/j.jinf.2020.04.008. Epub 2020 Apr 17.
6
C-reactive protein correlates with computed tomographic findings and predicts severe COVID-19 early.
J Med Virol. 2020 Jul;92(7):856-862. doi: 10.1002/jmv.25871. Epub 2020 Apr 25.
7
Diabetes is a risk factor for the progression and prognosis of COVID-19.
Diabetes Metab Res Rev. 2020 Oct;36(7):e3319. doi: 10.1002/dmrr.3319. Epub 2020 Apr 7.
8
Analysis of heart injury laboratory parameters in 273 COVID-19 patients in one hospital in Wuhan, China.
J Med Virol. 2020 Jul;92(7):819-823. doi: 10.1002/jmv.25809. Epub 2020 Apr 15.
9
Clinical and virological data of the first cases of COVID-19 in Europe: a case series.
Lancet Infect Dis. 2020 Jun;20(6):697-706. doi: 10.1016/S1473-3099(20)30200-0. Epub 2020 Mar 27.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验